Jun 23, 2010
By:
George Koroneos
Pfizer was forced (voluntarily) to put the kibosh on a fast-tracked Wyeth drug after some not-so-favorable postmarket data. Was this a good catch or an endemic problem with expedited drugs?
|
Jun 9, 2010
By:
George Koroneos
Merck has established a stable of 15 to 20 investigators focused solely on cancer compounds in an effort to boost efficiency and help move along the bevy of oncology products the firm has in its pipeline.
|
Jun 9, 2010
By:
George Koroneos
A new study indicates that doctors are no longer switching offices - largely due to current economic woes. What does this mean for sales reps? Pharm Exec interviews SK&A to find out more about its survey.
|
May 5, 2010
By:
George Koroneos
In the wake of megamergers and healthcare reform, Pfizer and Merck both produce fairly positive first quarter results
|
May 1, 2010
By:
George Koroneos
The new world of mobile applications is sparking creative platforms for reaching consumers and physicians.
|
Apr 28, 2010
By:
George Koroneos
After a year of losses, the biologics sector got a big boost in profits in 2009. However, with companies holding back on R&D spending and venture capitalists becoming more frugal, can the industry possibly see further growth?
|
Apr 14, 2010
By:
George Koroneos
The Prescription Drug User Fee Act will expire in 2012 and FDA is working hard to renegotiate the act before that end date. The contenders: in one corner, the pharma industry; in the other, the general public and consumers - and just about everyone has an opinion about what needs to be changed.
|
|
Pharm Exec presents the architects responsible for some of the year's most memorable and innovative pharmaceutical ads.
Apr 13, 2010
By:
George Koroneos
The faces and names behind the year's best pharmaceutical advertising.
|
Apr 7, 2010
By:
George Koroneos
Sales reps faced another round of layoffs last week as Sanofi-Aventis restructures its sales force due to looming generic competition and a dip in sales.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
